About the Authors
- Gerard J. P. van Westen
-
Affiliation Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands
- Jörg K. Wegner
-
Affiliation Tibotec BVBA, Beerse, Belgium
- Peggy Geluykens
-
Affiliation Tibotec BVBA, Beerse, Belgium
- Leen Kwanten
-
Affiliation Tibotec BVBA, Beerse, Belgium
- Inge Vereycken
-
Affiliation Tibotec BVBA, Beerse, Belgium
- Anik Peeters
-
Affiliation Tibotec BVBA, Beerse, Belgium
- Adriaan P. IJzerman
-
Affiliation Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands
- Herman W. T. van Vlijmen
-
Affiliations Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands, Tibotec BVBA, Beerse, Belgium
- Andreas Bender
-
* E-mail: ab454@cam.ac.uk
Affiliations Division of Medicinal Chemistry, Leiden/Amsterdam Center for Drug Research, Leiden, The Netherlands, Unilever Centre for Molecular Science Informatics, University of Cambridge, Cambridge, United Kingdom
Competing Interests
The authors have read the journal's policy and have the following conflicts: The Non-Nucleoside Reverse Transcriptase Inhibitiros Etravirine and Rilpivirine are marketed drugs developed by Tibotec, one of the funders of the current study. GJPvW was funded by Tibotec BVBA and JKW, PG, LK, IV, AP and HWTvV are employees of this company. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials, as detailed online in the guide for authors.
Author Contributions
Conceived and designed the experiments: GJPvW JKW API HWTvV AB. Performed the experiments: GJPvW PG LK IV AP. Analyzed the data: GJPvW JKW HWTvV AB. Contributed reagents/materials/analysis tools: GJPvW JKW PG LK IV AP API HWTvV AB. Wrote the paper: GJPvW JKW API HWTvV AB.